Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease

Table 1 General patient information n (%)

Gender ratio (male:female)	23:5
Age (yr)	25.9 ± 6.9 (13-36)
Mean follow-up (mo)	26.4 (14-41)
Surgical history
Hemorrhoidectomy	1 (3.6)
Perianal abscess drainage surgery	10 (35.7)
Anal fistula surgery	15 (53.6)
Previous medical therapy
Corticosteroids	6 (21.4)
Immunomodulator therapy	2 (7.1)
Infliximab	1 (3.6)
No therapy	19 (67.9)
Lesioned intestinal segment
Ileum	8 (28.6)
Colon	4 (14.3)
Ileocolon	14 (50.0)
Unable to assess	2 (7.1)
Types of fistula
Simple	5 (17.9)
Complex	23 (82.1)
Concomitant perianal diseases
Skin tag	4 (14.3)
Anal fissure	5 (17.8)
Anorectal stenosis	4 (14.3)
Other associated symptoms
Stomach pain	18 (64.3)
Diarrhea	13 (46.4)
Anemia	7 (25.0)
Fever	4 (14.3)

Table 2 Crohn's disease activity index/perianal Crohn's disease activity index/body mass index and related hematologic examination results before and after treatment (mean ± SD)

	Before treatment (week 0)	After treatment (week 30)	t value	P value
CDAI	205.47 ± 111.13	70.07 ± 77.54	9.974	0.000
PDAI	8.54 ± 4.89	0.93 ± 2.08	8.590	0.000
BMI	18.52 ± 2.84	21.36 ± 2.94	-6.447	0.000
CRP (mg/L)	25.61 ± 22.8	5.20 ± 5.39	4.244	0.000
ESR (mm/h)	25.29 ± 17.64	11.10 ± 6.9781	4.700	0.000
HB	121.21 ± 16.40	129.57 ± 17.64	-3.985	0.000
WBC (× 109/L)	7.27 ± 2.90	5.29 ± 1.41	3.713	0.001
N (%)	68.45 ± 8.69	52.39 ± 10.74	8.677	0.000
PLT (× 109/L)	267.88 ± 99.92	196.10 ± 63.22	4.441	0.000
ALB	39.68 ± 5.93	43.10 ± 3.89	-2.778	0.010

CDAI: Crohn's disease activity index; PDAI: Perianal Crohn's disease activity index; BMI: Body mass index; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; ALB: Albumin.